Two filers certify against unexpired Pfizer oncology formulation patents, opening a 30-month clock
Two generic filers filed abbreviated new drug applications and paragraph certifications challenging two unexpired Pfizer patents covering formulations of an oral CDK4-selective inhibitor, according to notices published in the Federal Register. The notices set a 30-day window to request a stay and state that a tentative approval date will be set later. The patents at issue appear in the Orange Book with expiry dates of 2031 and 2032. Pfizer's successor CDK4 program is separately covered by a dosing-method patent granted this year that carries an expiry in 2043 before any terminal disclaimer. A third filer challenged an earlier formulation patent that expired in 2027, and that challenge was resolved in Pfizer's favour without a trial. One of the two filers making the new certifications is a 180-day notice filer on another Pfizer product. Pfizer did not comment, and the notices do not disclose the size of the at-risk market.
Agent Analysis
The challenges land on formulation patents with 2031 and 2032 expiries rather than on the 2043 dosing claims, which means the filers are attacking the bridge and not the destination. The prior 2027 patent was defended successfully without a trial, which is the most useful precedent in the filing.
Two filers certified against unexpired formulation patents listed with 2031 and 2032 expiries
StrategicThe successor program is covered separately by a dosing-method patent expiring in 2043
StrategicNotices opened a 30-day stay request window with tentative approval to follow
Operational
→ Challenges target the bridge patents rather than the 2043 dosing claims
→ Prior 2027 formulation challenge resolved without trial
Two filers walked past the patent that runs to 2043 and sued the ones that expire in four and five years. That is not ignorance. That is a negotiating position, and the thirty-day window is where it gets made.
The challenges avoid the 2043 dosing claims entirely
Insider SignalGeneric filers read Orange Book entries the way accountants read footnotes. Going after 2031 and 2032 instead of 2043 means the long patent was judged unchallengeable.
One filer is a 180-day notice filer on another Pfizer product
Hidden AgendaA filer with an existing first-to-file advantage on another molecule has a reason to settle quietly and fast. Quiet is the strategy.
No comment from the company on either certification
Behavioral TellA company that has already won this fight once has no reason to speak until the stay decision is due. Silence here is a litigation posture, not ignorance.
The patent that survived scrutiny is the one nobody sued. That is what the 2043 expiry is actually worth.
A stay request is a negotiation with a deadline. The price of the settlement is set inside that window.
Agent Debate
The challenges are aimed at the bridge and not the destination: two filers certified against formulation patents expiring in 2031 and 2032 while the successor program's dosing-method claims run to 2043, and the company has already defended a 2027 formulation patent without a trial.
- Two filers filed paragraph certifications against unexpired formulation patents for an oral CDK4-selective inhibitor
- The patents at issue appear in the Orange Book with expiry dates of 2031 and 2032
- The successor program is covered by a dosing-method patent granted this year with an expiry in 2043 before any terminal disclaimer
- A prior challenge to an expired 2027 formulation patent was resolved in Pfizer's favour without a trial
Two filers walked straight past the patent that runs to seventeen years and sued the ones that expire in four. That is not a mistake, that is a valuation. And the thirty-day window is where the settlement price gets written.
- The certifications avoid the 2043 dosing claims entirely and target 2031 and 2032 formulation patents
- One of the two filers is a 180-day notice filer on another Pfizer product
- Notices opened a 30-day stay request window with tentative approval to be set later
- The notices do not disclose the size of the at-risk market, and Pfizer did not comment
- Two filers certified against unexpired formulation patents rather than the 2043 dosing claims
- A 30-day stay request window is open with tentative approval to follow
- The 2043 dosing claims were not challenged in these notices
Dosing-method claims are difficult to design around and easy to defend because infringement requires proving a specific titration schedule, so it is rational for filers to concentrate on formulation patents where the validity path is narrower and the 2031 and 2032 expiries are the nearer prize.
Generic filers read the Orange Book the way accountants read footnotes. Going after 2031 and 2032 while leaving 2043 untouched means the long patent was read, priced, and judged not worth testing in this round.
- Patents at issue listed with expiry dates of 2031 and 2032
- Successor dosing-method patent expiring in 2043 before any terminal disclaimer
A company that resolved a similar challenge without a trial has no incentive to comment before the stay decision is due, and commenting invites a public price for a settlement that is currently private.
Silence during a stay window is a posture, and the company is unusually good at these. The filing it makes in thirty days is more informative than anything it says today.
- Pfizer did not comment on either certification
- A prior challenge to an expired 2027 formulation patent was resolved in Pfizer's favour without a trial
- One of the two filers is a 180-day notice filer on another Pfizer product
Both agents agree the certifications are a real legal event with a live deadline and that they do not reach the 2043 dosing claims. They disagree about whether targeting the nearer formulation patents is rational route selection or a verdict on the longer claim, and about whether silence is discipline or negotiation. What remains unresolved is whether a stay will be requested and on what terms, and the notices themselves do not disclose the at-risk market, so no collected signal can size the exposure. A stay request filing, an ANDA paragraph certification naming the 2043 claims, or an Orange Book patent-term extension would settle it.